Potential biomarkers as a predictive factor of response to primary chemotherapy in breast cancer patients von Buono, F O, Pugliese, R D S, Silveira, W A da, Tirapelli, D P C, Reis, F J C Dos, Andrade, J M de, Carrara, H H A, Tiezzi, D G

Volltext

Obesity and high neutrophil-to-lymphocyte ratio are prognostic factors in non-metastatic breast cancer patients von Orlandini, L. F., Pimentel, F. F., de Andrade, J. M., dos Reis, F. J. C., de Mattos-Arruda, L., Tiezzi, D. G.

Volltext

Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors von Buzatto, I P C, Ribeiro-Silva, A, Andrade, J M, Carrara, H H A, Silveira, W A, Tiezzi, D G

Volltext

451 T-cell ligands expression profile in breast cancer is related to molecular subtype and cytolytic activity von Pimentel, F.F, Andrade, J.M. De, Carrara, H.H.A, Tiezzi, D.G

Volltext

Validation of the online PREDICT tool in a cohort of early breast cancer in Brazil von Magario, M.B, dos Santos, R.R, Teixeira, L.A, Tiezzi, D.G, Pimentel, F.F, Carrara, H.H.A, de Andrade, J.M, dos Reis, F.J. Candido

Volltext

1993P Integrative molecular and genomic analyses of trophoblast reveal GRB7, PGAP3, STARD3 and PSMD3 may orchestrate the lethal HER2-pathway signaling in carcinomas von Tiezzi, D.G., Poli-Neto, O.B.

Volltext

Breast conserving surgery after neoadjuvant therapy for large primary breast cancer von Tiezzi, D.G, Andrade, J.M, Marana, H.R.C, Zola, F.E, Peria, F.M

Volltext

92P Molecular/genomic profile enhances prediction of response to target therapy in HER2-positive breast cancer von Tiezzi, D.G., Buono, F.D.O., Fröhlich, A., Pagnotta, S.M.

Volltext

197P Computational pathology pipeline enables quantification of intratumor heterogeneity and tumor-infiltrating lymphocyte score von Tiezzi, D.G., Fröhlich, A., Chahud, F., Pagnota, S.

Volltext

113P Impact of local recurrence on disease-specific survival in breast cancer patients who underwent breast-conserving surgery von Tiezzi, D.G., de Mattos, L., Orlandini, L.F., Candido Dos Reis, F.J., Carrara, H.H., Rueda, O.M., Caldas, C., Andrade, J.M.D.

Volltext

CD86 expression may select patients for immune therapy in breast cancer von Tiezzi, D.G., Tiezzi, M., Da Silva, A.R., Andrade, J.M., Pimentel, F.F.

Volltext

Trastuzumab-Induced Myocardiotoxicity Mimicking Acute Coronary Syndrome von Ribeiro, K.B., Miranda, C.H., Andrade, J.M., Galli, L.G., Tiezzi, D.G., Oliveira, H.F., Zola, F.E., Volpe, G., Pazin-Filho, A., Peria, F.M.

Volltext

Tumour-Immune System Interactions in Breast Cancer: the Role of Pd-L1, Pd-L2 and Cd86 Expression von Pimentel, F.F., Chagas, E.R., Tiezzi, M.G., de Andrade, J.M., Tiezzi, D.G.

Volltext

171PTUMOUR-IMMUNE SYSTEM INTERACTIONS IN BREAST CANCER: THE ROLE OF PD-L1, PD-L2 AND CD86 EXPRESSION von Pimentel, F.F., Chagas, E.R., Tiezzi, M.G., de Andrade, J.M., Tiezzi, D.G.

Volltext

Germ cells and mammary gland transcritome comparison generate a powerful gene expression profile that predicts breast cancer survival von Tiezzi, D.G., Noushmehr, H., Silveira, W.A., Sabedot, T.S., Andrade, J.M.

Volltext

Research Article Expression of oncogenic microRNA-21 in neurospheres and attached cells of a glioblastoma cell line increased after treatment with temozolomide and ionizing radiati... von Rodrigues, A.R., Neto, F.S.L., Lourenço, L.G., Trevisan, F.A., Cirino, M. L.A., Nery, B., Peria, F.M., Pereira-da-Silva, G., Tazima, M.F.G.S., Tirapelli, L.F., Tiezzi, D.G., Junior, C.G. Carlotti, Tirapelli, D.P.C.

Volltext

Obesity and high neutrophil-to-lymphocyte ratio are prognostic factors in non-metastatic breast cancer patients von Orlandini, L.F., Pimentel, F.F., Andrade, J.M. de, Reis, F.J.C. dos, Mattos-Arruda, L. de, Tiezzi, D.G.

Volltext bestellen

Primary chemotherapy in breast cancer shows excellent clinical and pathological response with docetaxel and epirubicin von Marana, H.R.C., Andrade, J.M., Tiezzi, D.G., Taborda, M.F., Machetti, A.H., Carrara, H.H.A., Reis, F.J.C., Bighetti, S.

Volltext

Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors von I.P.C. Buzatto, A. Ribeiro-Silva, J.M. Andrade, H.H.A. Carrara, W.A. Silveira, D.G. Tiezzi

Volltext bestellen